Optimising Premixed Insulin Therapy in Type 2 Diabetes - Modern Premix Solutions Beyond BHI: Upgrading to NovoMix

Diabetes mellitus continues to pose a significant public health challenge globally and across sub-Saharan Africa. Despite the availability of multiple treatment options, a substantial proportion of patients with Type 2 Diabetes Mellitus (T2DM) fail to achieve recommended glycaemic targets. One of the major contributors to this gap is clinical inertia, delayed insulin initiation, and suboptimal treatment intensification.

This virtual Continuing Professional Development (CPD) training event will provide healthcare professionals with a comprehensive and clinically relevant update on premixed insulin therapy and its role in improving glycaemic control in patients with Type 2 diabetes.

Facilitated by the highly experienced Dr. Cecilia Kootin-Sanwu, the session will explore the evolving landscape of diabetes management, highlighting the limitations often encountered with conventional premixed insulin therapies and the clinical advantages of newer premix formulations. Participants will gain practical insights into patient selection, treatment optimisation, and evidence-based strategies for safely transitioning suitable patients to modern premixed insulin regimens.

Through a blend of expert presentations, practical clinical guidance, and interactive discussions, the programme aims to equip clinicians with practical tools to enhance treatment outcomes and improve patient quality of life in everyday clinical practice.

This highly engaging and informative session promises to be interactive, clinically practical, and directly relevant to healthcare professionals managing diabetes.

WHY YOU SHOULD ATTEND

Diabetes management continues to evolve rapidly, and clinicians must remain updated with practical strategies that improve patient outcomes without increasing treatment complexity. This training will help participants:

• Understand why many patients fail to achieve glycaemic targets despite treatment
• Identify when insulin intensification is clinically necessary
• Recognise the limitations of traditional premixed insulin therapy
• Learn practical strategies for switching patients safely and effectively
• Apply simple titration algorithms that improve treatment confidence
• Integrate evidence from large real-world studies into everyday clinical decision-making

Participants will leave the session with clear, practical, and immediately applicable insights to improve the care of patients living with diabetes.

EVENT HIGHLIGHTS

1. Expert-led training delivered by an experienced diabetes clinician

2. Concise clinical overview of diabetes and key treatment challenges

3. Updated insights on modern premixed insulin therapy

4. Evidence-based strategies for optimising glycaemic control

5. Practical guidance on insulin initiation, switching, and intensification

6. Simplified algorithms for titration and treatment adjustment

7. Case-based discussions drawn from real clinical practice

8. Review of evidence from large real-world clinical studies

9. Interactive question-and-answer session with participants

10. CPD accreditation available for eligible healthcare professionals

PROGRAMME CONTENT AND SESSION OVERVIEW

Introduction and Session Orientation

The session will begin with welcome remarks and an overview of the programme objectives. Participants will be introduced to the resource persons and provided with a brief outline of the structure of the training. This segment will also highlight the growing importance of simplicity, practicality, and patient-centred approaches in modern diabetes care.

Overview of Diabetes Mellitus

This section will provide a concise review of the epidemiology and global burden of diabetes, with particular attention to the rising prevalence of Type 2 Diabetes Mellitus. Participants will revisit the underlying pathophysiology of the disease and the long-term complications associated with poor glycaemic control. The discussion will also address the concept of clinical inertia and its significant impact on treatment outcomes and disease progression.

The Role of Insulin in Type 2 Diabetes

Participants will explore the clinical rationale for insulin therapy in the management of Type 2 diabetes, including when insulin initiation or intensification becomes necessary. The session will examine common challenges encountered with conventional premixed insulin therapies, particularly Biphasic Human Insulin (BHI), and review evolving clinical practice guidelines that inform current treatment strategies.

Modern Premixed Insulin Therapy

This segment will examine the clinical characteristics of modern premixed insulin formulations, including their pharmacokinetic and pharmacodynamic profiles. Participants will learn about the advantages these formulations offer in terms of predictability, dosing simplicity, and flexibility. Evidence from real-world studies demonstrating improvements in glycaemic outcomes and patient quality of life will also be reviewed.

Practical Switching Strategies in Clinical Practice

This section will provide practical guidance on transitioning appropriate patients from conventional insulin regimens to modern premixed insulin therapy. Participants will learn how to identify suitable candidates for switching, apply simplified initiation and titration algorithms, and address common concerns clinicians face during treatment transitions. Clinical case examples will be used to illustrate real-world application.

Product Presentation

A brief product presentation will provide additional insights into the featured premixed insulin therapy, including key clinical attributes, supporting evidence, and considerations for integration into routine diabetes management.

Interactive Question and Answer Session

Participants will have the opportunity to engage directly with the facilitator during an interactive question-and-answer session. This segment will allow clarification of clinical concepts, discussion of practical challenges, and sharing of professional experiences related to diabetes management.

Closing Remarks

The session will conclude with a recap of key learning points and final reflections from the facilitator. Participants will be encouraged to apply the knowledge gained in their clinical practice to improve patient outcomes in diabetes care.

PARTICIPANT CONSENT AND DATA PRIVACY NOTICE

By registering for this training programme, you consent to participate in the event hosted by Continuous Education Services (CES) on behalf of Novo Nordisk. Your registration information will be used solely for the purpose of facilitating the training programme and enabling the appropriate Continuing Professional Development (CPD) accreditation through the Medical and Dental Council (MDC).

CES is committed to safeguarding the privacy and confidentiality of participants. Your personal information will not be shared with Roche or any unrelated third parties. Data collected during registration will only be shared with relevant regulatory bodies, such as the Medical and Dental Council, strictly for the purpose of awarding CPD points for participation in this training. Participants are free to withdraw from the session at any time. If you choose to leave the meeting, no further action is required.

CES respects your privacy and is committed to ensuring that all information collected during this programme is handled with the highest level of confidentiality and in accordance with applicable data protection principles.

SUPPORTED BY

This will be a LIVE virtual event. Tuesday the 24th of March 2026. This event will be streamed live on this page.

Date: Tuesday the 24th of March 2026

Time: 1500 - 1700 GMT (3:00-5:00 pm Local Time) 

Target Audience: General Practitioners, Medical Officers, Specialist Registrars/Residents

The agenda is available to download in the downloads section.